Washington, D.C. | January 21, 2026 — The U.S. Food and Drug Administration (FDA) has taken a significant step toward improving food ingredient transparency by issuing a Request for Information (RFI) aimed at enhancing how gluten and gluten-related ingredients are disclosed on packaged food labels. The action focuses on improving consumer awareness and safety for people with celiac disease and gluten sensitivities by seeking public input on the prevalence of under-disclosed grain ingredients such as rye, barley, and oats and concerns around cross-contact gluten exposure. This transparent approach intends to help guide future labeling policy and regulatory decisions.
Science Significance
At its core, the FDA’s initiative reflects the importance of evidence-based food safety science, particularly in identifying and quantifying adverse health impacts of gluten-bearing ingredients. Although gluten labeling has long existed under “gluten-free” standards, emerging data gaps around cross-contact with non-wheat grains and limited U.S. information on associated adverse reactions have prompted this review. Input from scientific stakeholders, including researchers, clinicians, and consumer health advocates, will help shape a data-driven understanding of gluten’s effects on health conditions such as autoimmune celiac disease and non-celiac gluten sensitivity. The RFI thus serves as a bridge between scientific uncertainty and future regulatory research priorities.
Regulatory Significance
The FDA’s RFI is a regulatory planning tool that signals potential future action on food labeling standards under the Federal Food, Drug, and Cosmetic Act. By soliciting data on gluten ingredient disclosures and cross-contact issues, the agency is laying the groundwork for possible rulemaking or guidance that could standardize gluten labeling beyond existing voluntary claims. This step aligns with existing regulatory frameworks that require major allergens to be disclosed explicitly, and it highlights a proactive regulatory approach to address consumer health risks associated with hidden or poorly disclosed allergens. The input gathered will inform how the FDA prioritizes future protective measures and may lead to changes in labeling compliance requirements.
Business Significance
Advertisement
For food manufacturers, processors, and retail brands, the FDA’s request may herald a shift in ingredient transparency expectations that could affect production, packaging, and supply-chain documentation. Enhanced labeling requirements or future regulations based on the RFI responses could lead to adjustments in formulation practices, quality control checks, and labeling strategies to avoid misbranding or non-compliance. Given the growing consumer demand for clearer nutrition and allergen disclosure, companies that anticipate and adapt to potential regulatory shifts may gain competitive advantage, while those that lag could face operational and compliance challenges.
Patients’ Significance
The RFI directly impacts individuals with celiac disease and other gluten-related disorders by seeking to clarify how gluten-containing ingredients are declared on food products. Many consumers with health sensitivities currently navigate a landscape of varying label language and hidden cross-contact risks, making safe food choices difficult. Enhanced disclosure and possible future regulations could significantly reduce accidental gluten exposure, improving daily quality of life and health outcomes for patients. Public participation in the RFI process also empowers patient communities to share real-world experiences that may lead to stronger protections and more informed food choices in the future.
Policy Significance
This initiative intersects with broader policy goals around consumer protection, transparent labeling, and public health policy. It supports the administration’s focus on healthier food environments and aligns with strategic directives such as the Make America Healthy Again (MAHA) Strategy, which emphasizes ingredient transparency and diet-related disease prevention. By opening a formal comment period, the FDA reinforces the role of stakeholder engagement in policy formation, potentially influencing legislative or regulatory actions that standardize how food allergens and risk-related ingredients are communicated to the public.
The FDA’s move to enhance gluten ingredient disclosure represents a thoughtful and methodical approach to addressing a significant public health concern through science-informed regulatory planning. By inviting input from researchers, industry professionals, healthcare providers, and consumers, the agency is broadening the evidence base needed to consider future labeling improvements that protect individuals with celiac disease and gluten sensitivities. The outcomes of this RFI will help shape the next chapter in food ingredient transparency, regulatory policy, and consumer safety for years to come.
Source: U.S. Food and Drug Administration press release
